Beyond Seizure Control: Building the Infrastructure for Disease-Modifying Therapies in Epilepsy

Rapid advances in disease-modifying therapies (DMTs) for epilepsy, including gene-based therapies, antisense oligonucleotides, and stem cell-derived approaches, are reshaping the treatment landscape. As these therapies move through clinical trials and toward regulatory review, they introduce complex clinical, operational, ethical, and equity considerations that extend well beyond traditional antiseizure medication management. Successful integration will require careful attention to patient selection, genetic and biomarker testing, multidisciplinary care models, infrastructure readiness, referral pathways, long-term safety monitoring, informed consent for novel and potentially irreversible interventions, access to clinical trials, and cost and reimbursement challenges. Significant investments in personnel, systems, and facilities may be necessary, raising important questions about implementation across diverse practice settings and the risk of widening disparities in care. Here, we review the evolving therapeutic pipeline and outline key considerations for safe, ethical, and equitable implementation.

Authors

Institutions

Publication Details

Journal
Epiliepsy currents/Epilepsy currents
Published
2026-11-11
DOI
https://doi.org/10.1177/15357597261497536
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Beyond Seizure Control: Building the Infrastructure for Disease-Modifying Therapies in Epilepsy

Kunal Gupta, Julie M. Ziobro, Jack M. Parent, Anup D. Patel et al.
Epiliepsy currents/Epilepsy currents
Epilepsy research and treatment
article

Beyond Seizure Control: Building the Infrastructure for Disease-Modifying Therapies in Epilepsy

Kunal Gupta, Julie M. Ziobro, Jack M. Parent, Anup D. Patel, John Hixson, Erika Takle Axeen, Veronica L. Hood, Scott Demarest, Lacey A. Smith, Joseph E. Sullivan, Sucheta M. Joshi
article en

Abstract

Rapid advances in disease-modifying therapies (DMTs) for epilepsy, including gene-based therapies, antisense oligonucleotides, and stem cell-derived approaches, are reshaping the treatment landscape. As these therapies move through clinical trials and toward regulatory review, they introduce complex clinical, operational, ethical, and equity considerations that extend well beyond traditional antiseizure medication management. Successful integration will require careful attention to patient selection, genetic and biomarker testing, multidisciplinary care models, infrastructure readiness, referral pathways, long-term safety monitoring, informed consent for novel and potentially irreversible interventions, access to clinical trials, and cost and reimbursement challenges. Significant investments in personnel, systems, and facilities may be necessary, raising important questions about implementation across diverse practice settings and the risk of widening disparities in care. Here, we review the evolving therapeutic pipeline and outline key considerations for safe, ethical, and equitable implementation.

Epiliepsy currents/Epilepsy currents
University of Southern California (US), Boston Children's Hospital (US), Nationwide Children's Hospital (US), Children's Hospital of Los Angeles (US), Medical College of Wisconsin (US), University of Michigan (US), Dravet Syndrome Foundation (US), University of California System (US), Children's Hospital Colorado (US), VA Ann Arbor Healthcare System (US), University of Virginia (US)
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon